Review of HER2 Immunohistochemistry and in Situ Hybridisation Concordance in Breast Cancer

Pathology- United States

doi 10.1016/j.pathol.2020.01.279

Full Text

Abstract

Available in

Date

February 1, 2020

Authors

Jeremy N. Pulvers

Angela Y. Wong

Lisa H. Tan

Publisher

Elsevier BV

Related search

High Concordance Between Immunohistochemistry and Fluorescence in Situ Hybridization Testing for HER2 Status in Breast Cancer Requires a Normalized IHC Scoring System

English

Comparison of Fluorescence In-Situ Hybridisation With Dual-Colour In-Situ Hybridisation for Assessment of HER2 Gene Amplification of Breast Cancer in Hong Kong

Hong Kong Medical Journal

Medicine

2016

English

Critical Evaluation ofKCNJ3gene Product Detection in Human Breast Cancer: mRNA in Situ Hybridisation Is Superior to Immunohistochemistry

Journal of Clinical Pathology

English

Immunohistochemistry of Detection HER2 on Breast Cancer in Basra City

Scientific Journal of Medical Research

2019

English

Necessity of in Situ Hybridization Test of Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Patients With Equivocal HER2 Immunohistochemistry Results

Journal of Breast Disease

2018

English

Comparison of Immunohistochemistry and Fluorescence in Situ Hybridization for the Analysis of Her2/Neu and Topoisomerase Ii-Alpha Status in Human Breast Cancer

Turk Patoloji Dergisi

Forensic Medicine

Pathology

2010

English

Gene Amplification and Protein Expression of EGFR and HER2 by Chromogenic in Situ Hybridisation and Immunohistochemistry in Atypical Adenomatous Hyperplasia and Adenocarcinoma of the Lung

Journal of Clinical Pathology

English

Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study

European Journal of Breast Health

2018

English

Pmd31 - The Concordance and Budget Impact of Multiple Er, Pr and Her2 Determinations in Dutch Breast Cancer Patients

English

Amanote Research

Review of HER2 Immunohistochemistry and in Situ Hybridisation Concordance in Breast Cancer

Pathology- United States

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

High Concordance Between Immunohistochemistry and Fluorescence in Situ Hybridization Testing for HER2 Status in Breast Cancer Requires a Normalized IHC Scoring System

Comparison of Fluorescence In-Situ Hybridisation With Dual-Colour In-Situ Hybridisation for Assessment of HER2 Gene Amplification of Breast Cancer in Hong Kong

Critical Evaluation ofKCNJ3gene Product Detection in Human Breast Cancer: mRNA in Situ Hybridisation Is Superior to Immunohistochemistry

Immunohistochemistry of Detection HER2 on Breast Cancer in Basra City

Necessity of in Situ Hybridization Test of Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Patients With Equivocal HER2 Immunohistochemistry Results

Comparison of Immunohistochemistry and Fluorescence in Situ Hybridization for the Analysis of Her2/Neu and Topoisomerase Ii-Alpha Status in Human Breast Cancer

Gene Amplification and Protein Expression of EGFR and HER2 by Chromogenic in Situ Hybridisation and Immunohistochemistry in Atypical Adenomatous Hyperplasia and Adenocarcinoma of the Lung

Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study

Pmd31 - The Concordance and Budget Impact of Multiple Er, Pr and Her2 Determinations in Dutch Breast Cancer Patients